Anti-vascular Endothelial Growth Factor Therapeutics Market By Drug Type (Bevacizumab, Ranibizumab, Aflibercept, Brolucizumab), By Application (Ophthalmology {Age-related Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion}, Oncology {Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer}, Other Indications), By Delivery Route (Intravitreal Injection, Intravenous Injection), By End-User (Hospitals, Specialty Clinics, Ambulatory Centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Drug Type

• Bevacizumab
• Ranibizumab
• Aflibercept
• Brolucizumab
• Other

 By Application

• Ophthalmology
  • Age-related Macular Degeneration
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
• Oncology
  • Colorectal Cancer
  • Non-Small Cell Lung Cancer
  • Breast Cancer
• Other Indications

By Delivery Route

• Intravitreal Injection
• Intravenous Injection

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Roche
• Regeneron Pharmaceuticals
• Novartis
• Bayer AG
• Eli Lilly and Company
• Amgen Inc.
• Pfizer Inc.
• Sanofi
• AstraZeneca
• Merck & Co., Inc.
• Teva Pharmaceutical Industries
• Bristol-Myers Squibb
• GlaxoSmithKline
• Bausch & Lomb
• Alcon Laboratories
• Santen Pharmaceutical Co., Ltd.
• Haplo Therapeutics
• Zymeworks Inc.